| A comprehensive map of molecular drug targets R Santos, O Ursu, A Gaulton, AP Bento, RS Donadi, CG Bologa, ... Nature reviews Drug discovery 16 (1), 19-34, 2017 | 2762 | 2017 |
| The design of leadlike combinatorial libraries SJ Teague, AM Davis, PD Leeson, T Oprea Angewandte Chemie International Edition 38 (24), 3743-3748, 1999 | 1165 | 1999 |
| BDDCS, the Rule of 5 and drugability LZ Benet, CM Hosey, O Ursu, TI Oprea Advanced drug delivery reviews 101, 89-98, 2016 | 1111 | 2016 |
| Is There a Difference Between Leads and Drugs? A Historical Perspective. TI Oprea, AM Davis, SJ Teague, PD Leeson Journal of chemical information and computer sciences 41 (5), 1308-1315, 2001 | 1095 | 2001 |
| Virtual and biomolecular screening converge on a selective agonist for GPR30 CG Bologa, CM Revankar, SM Young, BS Edwards, JB Arterburn, ... Nature chemical biology 2 (4), 207-212, 2006 | 999 | 2006 |
| QSAR without borders EN Muratov, J Bajorath, RP Sheridan, IV Tetko, D Filimonov, V Poroikov, ... Chemical Society Reviews 49 (11), 3525-3564, 2020 | 972 | 2020 |
| Property distribution of drug-related chemical databases TI Oprea Journal of computer-aided molecular design 14 (3), 251-264, 2000 | 842 | 2000 |
| Estrogen signaling through the transmembrane G protein–coupled receptor GPR30 ER Prossnitz, JB Arterburn, HO Smith, TI Oprea, LA Sklar, HJ Hathaway Annu. Rev. Physiol. 70 (1), 165-190, 2008 | 812 | 2008 |
| BDDCS applied to over 900 drugs LZ Benet, F Broccatelli, TI Oprea The AAPS journal 13 (4), 519-547, 2011 | 785 | 2011 |
| Pursuing the leadlikeness concept in pharmaceutical research MM Hann, TI Oprea Current opinion in chemical biology 8 (3), 255-263, 2004 | 705 | 2004 |
| In vivo effects of a GPR30 antagonist MK Dennis, R Burai, C Ramesh, WK Petrie, SN Alcon, TK Nayak, ... Nature chemical biology 5 (6), 421-427, 2009 | 653 | 2009 |
| Distribution and characterization of estrogen receptor G protein-coupled receptor 30 in the rat central nervous system E Brailoiu, SL Dun, GC Brailoiu, K Mizuo, LA Sklar, TI Oprea, ER Prossnitz, ... Journal of endocrinology 193 (2), 311-321, 2007 | 637 | 2007 |
| How many rare diseases are there? M Haendel, N Vasilevsky, D Unni, C Bologa, N Harris, H Rehm, ... Nature reviews drug discovery 19 (2), 77-78, 2020 | 609 | 2020 |
| G protein–coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17β-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells L Albanito, A Madeo, R Lappano, A Vivacqua, V Rago, A Carpino, ... Cancer research 67 (4), 1859-1866, 2007 | 549 | 2007 |
| Temporal disease trajectories condensed from population-wide registry data covering 6.2 million patients AB Jensen, PL Moseley, TI Oprea, SG Ellesøe, R Eriksson, H Schmock, ... Nature communications 5 (1), 4022, 2014 | 500 | 2014 |
| Unexplored therapeutic opportunities in the human genome TI Oprea, CG Bologa, S Brunak, A Campbell, GN Gan, A Gaulton, ... Nature reviews Drug discovery 17 (5), 317-332, 2018 | 468 | 2018 |
| Drug repurposing from an academic perspective TI Oprea, JE Bauman, CG Bologa, T Buranda, A Chigaev, BS Edwards, ... Drug Discovery Today: Therapeutic Strategies 8 (3-4), 61-69, 2011 | 429 | 2011 |
| Chemography: the art of navigating in chemical space TI Oprea, J Gottfries Journal of combinatorial chemistry 3 (2), 157-166, 2001 | 428 | 2001 |
| Therapies for rare diseases: therapeutic modalities, progress and challenges ahead E Tambuyzer, B Vandendriessche, CP Austin, PJ Brooks, K Larsson, ... Nature Reviews Drug Discovery 19 (2), 93-111, 2020 | 427 | 2020 |
| Integrating virtual screening in lead discovery TI Oprea, H Matter Current opinion in chemical biology 8 (4), 349-358, 2004 | 405 | 2004 |
Cristian BologaResearch Professor, University of New MexicoVerified email at salud.unm.edu
